drugset / Press release
In April 2026, minimal Grade 2 infusion related reactions (IRRs) were observed in all patients enrolled in the ongoing Qurgen Clinical trial with 48-hour continuous IV infusion using an infusion pump. This new drug infusion regimen significantly enhanced the safety of SON-DP drug.
The release as fetched from its publisher. qurgen.com ↗